Nuvig Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2021-01-01
- Employees
- 11
- Market Cap
- -
Safety, Tolerability, and Efficacy of NVG-2089 in Participants With CIDP
Phase 2
Recruiting
- Conditions
- Chronic Inflammatory Demyelinating Polyneuropathy
- Interventions
- First Posted Date
- 2025-06-18
- Last Posted Date
- 2025-06-18
- Lead Sponsor
- Nuvig Therapeutics, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT07027111
- Locations
- 🇺🇸
Nuvig Site, Denton, Texas, United States